|
US7727713B2
(en)
|
2001-06-20 |
2010-06-01 |
Nuevolution A/S |
Templated molecules and methods for using such molecules
|
|
US10731151B2
(en)
|
2002-03-15 |
2020-08-04 |
Nuevolution A/S |
Method for synthesising templated molecules
|
|
AU2003247266A1
(en)
|
2002-08-01 |
2004-02-23 |
Nuevolution A/S |
Multi-step synthesis of templated molecules
|
|
CN102838654B
(zh)
|
2002-10-30 |
2016-05-18 |
纽韦卢森公司 |
合成双功能复合物的方法
|
|
DE60330406D1
(de)
|
2002-12-19 |
2010-01-14 |
Nuevolution As |
Durch quasizufallsstrukturen und funktionen geführte synthesemethode
|
|
US20070026397A1
(en)
|
2003-02-21 |
2007-02-01 |
Nuevolution A/S |
Method for producing second-generation library
|
|
ATE447626T1
(de)
|
2003-09-18 |
2009-11-15 |
Nuevolution As |
Methode zur gewinnung struktureller informationen kodierter moleküle und zur selektion von verbindungen
|
|
PL2253614T3
(pl)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
|
JP5230865B2
(ja)
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap結合性化合物
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
EA012810B1
(ru)
|
2005-02-25 |
2009-12-30 |
Тетралоджик Фармасеутикалс |
Димерные ингибиторы ингибиторов белков апоптоза (iap)
|
|
WO2006122408A1
(en)
|
2005-05-18 |
2006-11-23 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
JP2008545008A
(ja)
*
|
2005-06-30 |
2008-12-11 |
プロシディオン・リミテッド |
Gpcrアゴニスト
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
DE102005046907A1
(de)
|
2005-09-30 |
2007-04-12 |
Voith Patent Gmbh |
Verfahren und Vorrichtung zur Herstellung einer Tissuebahn
|
|
AU2006308453B9
(en)
|
2005-10-25 |
2011-12-01 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
LT3018206T
(lt)
|
2005-12-01 |
2021-12-10 |
Nuevolution A/S |
Fermentiniai kodavimo būdai, skirti didelių bibliotekų efektyviai sintezei
|
|
WO2007106192A2
(en)
*
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
|
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics, Inc. |
composto de ligação de domìnio bir da iap
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
MX2009000824A
(es)
*
|
2006-07-24 |
2009-02-04 |
Tetralogic Pharmaceuticals Cor |
Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
JP5452223B2
(ja)
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Iap阻害剤
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
AU2007307763A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
CA2684169C
(en)
|
2007-04-12 |
2012-06-19 |
Joyant Pharmaceuticals, Inc. |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
|
NZ598890A
(en)
*
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法
|
|
JP5176452B2
(ja)
*
|
2007-09-27 |
2013-04-03 |
住友化学株式会社 |
光学活性なテトラヒドロピラニルグリシン化合物の製造方法
|
|
DK2240506T3
(da)
*
|
2008-01-11 |
2013-04-08 |
Genentech Inc |
IAP inhibitorer
|
|
WO2009094224A1
(en)
|
2008-01-25 |
2009-07-30 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
|
|
TW201011006A
(en)
*
|
2008-06-16 |
2010-03-16 |
Nuevolution As |
IAP binding compounds
|
|
US8835393B2
(en)
|
2008-08-02 |
2014-09-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック, インコーポレイテッド |
Iapのアザインドールインヒビター
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
JP2012516329A
(ja)
|
2009-01-30 |
2012-07-19 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
Pi3k阻害剤としてのヘテロアリールおよびその使用
|
|
RU2404166C1
(ru)
*
|
2009-04-14 |
2010-11-20 |
Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран |
Способ получения 1-ацетилизохинолина
|
|
US8283372B2
(en)
*
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
UY32826A
(es)
|
2009-08-04 |
2011-02-28 |
Takeda Pharmaceutical |
Compuestos heterocíclicos
|
|
MX351274B
(es)
|
2009-08-12 |
2017-10-06 |
Novartis Ag |
Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
|
|
JP2013505446A
(ja)
|
2009-09-18 |
2013-02-14 |
ノバルティス アーゲー |
Iap阻害剤化合物のためのバイオマーカー
|
|
EP2493879B1
(en)
|
2009-10-28 |
2014-05-14 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
MY159958A
(en)
*
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
SI2558577T1
(sl)
|
2010-04-16 |
2019-05-31 |
Nuevolution A/S |
Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
|
|
US9062038B2
(en)
|
2010-08-11 |
2015-06-23 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
BR112013023798A2
(pt)
|
2011-03-22 |
2016-09-20 |
Syngenta Participations Ag |
compostos inseticidas
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
CN102757426A
(zh)
*
|
2011-04-28 |
2012-10-31 |
中国医学科学院医药生物技术研究所 |
一种苯并异恶唑基取代的噻唑类化合物、制备方法及用途
|
|
NO2755614T3
(cg-RX-API-DMAC7.html)
|
2012-01-03 |
2018-03-31 |
|
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
KR20150011822A
(ko)
|
2012-05-04 |
2015-02-02 |
노파르티스 아게 |
Iap 억제제 요법을 위한 바이오마커
|
|
GB201218850D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201218862D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201218864D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
US9980973B2
(en)
|
2012-10-19 |
2018-05-29 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
|
EP2963125B1
(en)
|
2013-02-15 |
2020-09-30 |
National University Corporation Tokyo Medical and Dental University |
Therapeutic agent for treating a cancer in which nrf2 is stabilized
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN115368356B
(zh)
|
2013-12-20 |
2025-05-09 |
阿斯特克斯治疗有限公司 |
双环杂环化合物及其治疗用途
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
CN110944719A
(zh)
*
|
2017-07-25 |
2020-03-31 |
合帕吉恩治疗公司 |
凋亡蛋白的二聚肽抑制剂
|
|
CN111247161B
(zh)
*
|
2017-11-13 |
2021-12-31 |
正大天晴药业集团股份有限公司 |
用作iap抑制剂的smac模拟物及其用途
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
TWI812673B
(zh)
|
2018-02-12 |
2023-08-21 |
美商富曼西公司 |
用於防治無脊椎害蟲之萘異噁唑啉化合物
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
CN119219628A
(zh)
|
2018-09-07 |
2024-12-31 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019409132B2
(en)
|
2018-12-21 |
2026-08-06 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US12240855B2
(en)
|
2019-03-06 |
2025-03-04 |
Daiichi Sankyo Company, Limited |
Pyrrolopyrazole derivative
|
|
WO2020228642A1
(zh)
*
|
2019-05-10 |
2020-11-19 |
正大天晴药业集团股份有限公司 |
一种用作iap抑制剂的smac模拟物的结晶及其制备方法
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US12678509B2
(en)
|
2019-11-08 |
2026-07-14 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitor of apoptosis (IAP) protein antagonists
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
CN113354530B
(zh)
*
|
2020-03-07 |
2025-11-18 |
东莞市东阳光动物保健药品有限公司 |
一种制备4-乙酰基-1-萘甲酸的方法
|
|
HUP2200468A1
(hu)
|
2020-04-29 |
2023-03-28 |
X Chem Zrt |
IAP antagonisták és gyógyászati alkalmazásuk
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2025524064A
(ja)
|
2022-07-26 |
2025-07-25 |
ノバルティス アーゲー |
Akr1c3依存性kars阻害剤の結晶形態
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|